Speaker Profile

Ph.D., Executive Chair, Angarus Therapeutics

Dr. Liu founded several biotech startups and Angarus Therapeutics. He helps academic researchers to advance their research work into commercial product development. His contribution to these endeavors by providing the initial funding to jump-start the process, working with the scientific co-founders to transfer their research into commercial entities through a licensing agreement with their institutes, hiring outside experts to manage intellectual property protections, recruiting company’s executives, raising the first round of funding and initiating clinical programs.

Immunotherapy Showcase:
Angarus Therapeutics

Angarus Therapeutics is developing checkpoint inhibitors in the innate immunity STING pathway. Our animal cancer models data demonstrate that a combination of checkpoint blockers, both innate and adaptive, leads to long term survival.

Development Of An Innate Immune Checkpoint Inhibitor
We created novel inhibiting molecules of ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1), demonstrated that these molecules have anti-tumor activity as monotherapy or in combination with a second agent in animal cancer models, including triple negative breast cancer, pancreatic cancer, neuroblastoma, and colon cancer.

 Session Abstract – PMWC 2020 Silicon Valley

Track 6 - January 23 9.00 A.M.-10.45 A.M.

The PMWC 2020 Immunotherapy Showcase will provide a 15-minute time slot for selected immunotherapy companies to present their latest technologies and advancements to an audience of leading investors, potential clients, and partners. We will hear from companies building new cell-based immunotherapies, work in the growing area of cancer vaccines, that help understand the relevance of the tumor microenvironment, accelerate the patient selection process, or otherwise work towards overcoming to challenges related to therapeutic discovery.